Table of Content . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ Form 10-K ____________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition pe ...

盈利加速 - 公司的盈利增长是吸引投资者的关键因素，尤其是盈利加速对提升股价效果更佳[1] - 盈利加速是指公司每股盈利的增长率逐步提高，如果在规定时间内公司的季度盈利增长率增加，就可以称之为盈利加速[3] - 盈利加速有助于发现尚未引起投资者注意的股票，一旦引起关注，股价必然会上涨，因为盈利加速考虑了增长率的方向和幅度[4]

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate rev ...

Have you been paying attention to shares of AxoGen (AXGN) ? Shares have been on the move with the stock up 8.8% over the past month. The stock hit a new 52-week high of $10.65 in the previous session. AxoGen has gained 51.8% since the start of the year compared to the 7.9% move for the Zacks Medical sector and the 6.3% return for the Zacks Medical - Instruments industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus e ...

盈利增长 - 盈利增长吸引了几乎所有人的注意，从高层管理人员到研究分析师[1] 盈利加速 - 盈利加速在提升股价时效果更好。研究表明，大多数成功的股票在股价上涨之前都经历了盈利加速[2] - 盈利加速是指公司每股盈利（EPS）的递增增长。换句话说，如果公司的季度盈利增长率在规定的时间范围内增加，就可以称之为盈利加速[3]

ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2023 fourth quarter and full-year financial results on Tuesday, March 5, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference ca ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment and appointment of John Manning to the position of Area Vice President of Sales. Mr. Manning will report to Doris Quackenbush, Vice President of Sales. In connection with the commencement of his employm ...

Axogen, Inc.（NASDAQ:AXGN） - Axogen, Inc.宣布REPOSE临床研究取得了积极的顶线结果，比较了标准神经切除术和使用Axoguard Nerve Cap保护末端神经的神经切除术，达到了减少疼痛的主要终点[1] - Axoguard Nerve Cap在随访过程中显示出与标准治疗神经切除术相比，参与者报告的总疼痛减少方面具有统计学上的优势[1] Axogen产品介绍 - Axogen是一家专注于周围神经再生和修复技术的领先公司，产品包括Avance®神经移植物、Axoguard Nerve Connector®、Axoguard Nerve Protector®、Axoguard HA+ Nerve Protector™和Axoguard Nerve Cap®[8]

财务数据和关键指标变化 - 第三季度收入为4.13亿美元,同比增长12% [12][36] - 毛利润为3.32亿美元,毛利率为80.5%,同比下降2.8个百分点 [37][49] - 经营费用增加5%至3.73亿美元 [38] - 销售及营销费用增加8%至2.14亿美元,占收入比重下降至52% [39] - 研发费用维持平稳,占收入比重下降至17% [40][41] - 净亏损为410万美元,调整后净收益为70万美元 [42] - 调整后EBITDA为240万美元,同比增加200万美元 [43] 各条业务线数据和关键指标变化 - 紧急创伤业务占收入约50%,同比中个位数增长 [13][14][36] - 预约手术业务占收入约50%,同比增长约20% [15][16][36] - 核心账户数量增加12%至372个,占收入比重增至65% [17][18] 各个市场数据和关键指标变化 - 医院运营环境趋于稳定,一些常规手术开始从门诊转回医院 [14][15] - 一些简单创伤手术转移至门诊手术中心,但公司仍能进入这些市场 [59][60] 公司战略和发展方向及行业竞争 - 继续专注于临床数据、创新、市场开发和商业执行,推动外科医生采用和增长 [33] - 正在开发新的神经保护产品Axoguard HA+和Avive+ Soft Tissue Matrix [23][24][25] - 正在推进Avance神经移植物的生物制品许可申请(BLA),预计2025年获批 [30][31][32] - 新的生产设施已投入使用,为未来增长提供三倍产能 [30] 管理层对经营环境和未来前景的评论 - 医院运营环境趋于稳定,一些常规手术从门诊转回医院 [14][15] - 公司有望通过提高销售团队生产力来推动收入增长 [19] - 新产品创新和临床数据将是公司长期增长的驱动力 [21][22][26][27][28] - 公司有信心维持良好的资产负债表,实现现金流平衡和盈利 [46][47] 问答环节重要的提问和回答 问题1 **Michael Sarcone 提问** 第四季度收入指引中的假设 [56][57] **Pete Mariani 回答** 公司维持中间值指引,认为这对公司来说是合适的 [57] 问题2 **Unidentified Analyst 提问** Avance神经移植物BLA获批对使用量的影响 [63][64][65] **Karen Zaderej 回答** BLA批准将有助于中间采用者接受Avance的优势,并提高手术效率 [65][66] 问题3 **Caitlin Cronin 提问** 核心账户占比提升的原因 [69][70][71] **Karen Zaderej 回答** 公司深入核心账户的策略奏效,通过扩大创伤和预约手术业务实现了增长 [70][71]